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Abstract
Introduction: Sample enrichment is a key factor in contemporary early-detection strategies aimed at the identification of 
help-seekers at increased risk of imminent transition to psychosis. We undertook a meta-analytic investigation to ascertain 
the role of sample enrichment in the recently highlighted negative prognostic effect of baseline antipsychotic (AP) exposure 
in clinical high-risk (CHR-P) of psychosis individuals.
Methods: Systematic review and meta-analysis of all published studies on CHR-P were identified according to a validated 
diagnostic procedure. The outcome was the proportion of transition to psychosis, which was calculated according to the 
Freeman‐Tukey double arcsine transformation.
Results: Thirty-three eligible studies were identified, including 16 samples with details on AP exposure at baseline and 17 
samples with baseline AP exposure as exclusion criterion for enrollment. Those with baseline exposure to AP (n = 395) had 
higher transition rates (29.9%; 95% CI: 25.1%–34.8%) than those without baseline exposure to AP in the same study (n = 1289; 
17.2%; 15.1%–19.4%) and those coming from samples that did not include people who were exposed to AP at baseline (n = 2073; 
16.2%; 14.6%–17.8%; P < .05 in both the fixed-effects and the random-effects models). Heterogeneity within studies was 
substantial, with values above 75% in all comparisons.
Conclusions: Sample enrichment is not a plausible explanation for the higher risk of transition to psychosis of CHR-P 
individuals who were already exposed to AP at the enrollment in specialized early-detection programs. Baseline exposure to 
AP at CHR-P assessment is a major index of enhanced, imminent risk of psychosis.
Keywords:  Antipsychotic, clinical high risk, prevention, prognosis, psychosis, treatment
Introduction
Research on clinical high-risk for psychosis (CHR-P) is central 
for the deployment of suitable clinical care pathways aiming at 
preventing (or mitigating) the biopsychosocial consequences of 
psychosis. In the last 30 years, the early-detection field has been 
engaged in a robust effort to conceptualize and develop prog-
nostic models for trans-diagnostic staging and individualized 
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risk stratification (see Sanfelici et  al., 2020 for an overview). 
However, in such tumultuous growth, the accelerated search for 
scalable predictors has led to some undetected distortion, such 
as the neglect of obvious clinical confounders. This is the case 
of baseline exposure to antipsychotics (AP) in individuals en-
rolled within the CHR-P group (Raballo et al., 2019, 2020a,b, 2021; 
Raballo and Poletti, 2019).
There is indeed substantial meta-analytical evidence that 
almost 1 out of 5/4 individuals enrolled as CHR-P in specialist 
centers is already undergoing AP treatment at the moment of 
the first CHR-P evaluation (Raballo et al., 2019, 2020a,b). Needless 
to say, such exposure may alter the clinical presentation (e.g., 
modulating the frequency or severity of positive psychotic 
symptoms during the CHR assessment) as well as the natural 
course of transition to psychosis (see Raballo et al., 2019 for a 
synthetic overview). Even more crucially, there is meta-analytic 
evidence that baseline AP exposure in CHR-P individuals is asso-
ciated with an even higher imminent risk of transition to psych-
osis (Raballo et al., 2020a,b).
The magnitude of this confounder and its implications 
for the field have been overlooked until recently (Raballo and 
Poletti, 2019). Among other things (e.g., reduced precision of 
current prognostic estimates and risk stratification), the wide-
spread conflation of AP-naïve and AP-exposed help-seekers in 
the same CHR-P group might hamper the identification of the 
effectiveness of new pharmacological and non-pharmacological 
treatments, given that a treatment that is effective in AP-naïve 
CHR-P individuals may be less effective in AP-exposed help-
seekers (who might already be in a first-episode psychosis even 
if psychometrically attenuated due to the AP treatment).
Most importantly, there is meta-analytic evidence that CHR-P 
individuals undergoing AP treatment at the time of enrollment 
have different longitudinal trajectories and risk of transition to 
psychosis compared with AP-naïve CHR-P patients (29% vs 16%: 
risk ratio of transition 1.47 in the fixed-effects model) (Raballo 
et al., 2020b). This suggests that (1) baseline AP treatment plaus-
ibly signals an increased clinical severity (although still formally 
within the psychometric criteria for CHR-P), which is associated 
with increased risk of longitudinal transition to psychosis; and/
or (2) the AP-exposed CHR group at baseline presumably in-
cludes a fraction of “pharmacologically attenuated first-episode 
psychosis” that have a higher likelihood to convert into psycho-
metric full-blown psychosis.
However, another explanatory hypothesis is also possible, 
that is, that the higher conversion rates in AP-exposed CHR-P 
might be an epiphenomenon of the enrichment strategies 
adopted in the different study settings (aka pretest risk enrich-
ment). Concretely, it is possible that the different recruitment 
and sampling strategies in the studies could lead to different 
pretest prevalence of more severe cases across the CHR-P cen-
ters (Fusar-Poli et al., 2016, 2017).
The guiding question of the current meta-analytic investi-
gation is therefore the following: is pre-test risk enrichment the 
key to the apparent negative prognostic effect of baseline anti-
psychotic exposure in CHR-P?
Aim
The current study was designed to test the possible hidden role 
of pretest risk enrichment on the (previously demonstrated) 
impact of baseline AP on CHR-P transition to psychosis risk. 
We wanted to verify if AP-naïve CHR-P participants present 
similar transition prevalence independently if they belong to 
CHR-P samples that exclude baseline AP exposure (i.e., pure 
AP-naïve CHR-P source samples) or from CHR-P samples that 
allow the inclusion of help-seekers under ongoing AP treatment 
at baseline (i.e., source samples encompassing both AP-naïve 
and AP-exposed CHR-P). Therefore, we meta-analytically con-
trasted the risk of transition in 3 sub-populations: CHR-P with 
baseline exposure to AP, CHR-P without baseline exposure to AP 
who were enrolled from the same source studies, and CHR-P 
enrolled in studies having AP exposure as explicit exclusion 
criterion.
Indeed, we expected that, should higher pretest risk en-
richment be involved in the higher transition rates of baseline 
AP-exposed CHR-P, the overall transition rate of AP-naïve CHR-P 
drawn from these latter samples should be higher than one of 
those AP-naïve CHR-P from samples that never enrolled individ-
uals undergoing AP treatment at baseline.
Methods
Study Selection
The systematic review and meta-analysis were planned 
and executed according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses guidelines (Moher et al., 
2009). We searched PubMed/Medline and the Cochrane library 
from inception up to October 30, 2020, by using the following key 
terms: “Ultra high risk” OR “Clinical high risk” AND “psychosis“ 
AND “transition” OR “conversion.” This search retrieved 1842 art-
icles, of which 98 were systematic review or meta-analysis, in 
PubMed/Medline and 196 trials in the Cochrane Central Register 
of Controlled Trials. Two authors (M.P., A.P.) evaluated the list of 
extracted articles and decided about inclusion or exclusion ac-
cording to the following criteria:
 − Written in English;
 − Details information about samples with people diagnosed 
at CHR-P of psychosis based on a validated diagnostic pro-
cedure (i.e., using an interview and formal criteria to deter-
mine the CHR-P status of the participants);
Significance Statement
Major guidelines do not indicate antipsychotic medication as first-line treatment for the prevention of psychosis in individuals 
at clinical high risk (CHR-P). Despite that, recent meta-analyses reveal that the use of such medications is relatively widespread 
in the field and seems to be associated with higher imminent risk of transition to psychosis. Therefore, we wished to test if such 
increased risk could reflect differences in pre-recruitment risk enrichment (aka pre-test risk enrichment) across the studies ra-
ther than medication exposure. We found, however, that despite heterogeneities in referral and sampling strategies, pre-test risk 
enrichment in CHR-P does not seem to play any specific role in the observed negative prognostic effect of baseline antipsychotic 
exposure. Given the intuitive implications for the treatment of psychosis and the prevention of its undesired long-term out-
comes, the results urge further investigations on the clinical effects of antipsychotic medications in young help-seekers at high 
risk for psychosis.
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 − Reports numeric data about the sample and the outcome 
at a predefined follow-up time, and has transition to psych-
osis as one of the outcomes;
 − Reports AP exposure as exclusion criterion, or in case of in-
clusion of participants on AP, reports raw data on AP base-
line exposure in relation to the transition outcome.
Data Extraction
After exclusion of duplicates (including articles repeatedly re-
porting the results of the same trial or with overlapping samples) 
and articles that were unrelated to the main topic (i.e., studies 
on brain imaging or genetic markers), individual studies were in-
cluded when they matched the inclusion criteria. Discrepancies 
were solved by discussion consulting a third experienced re-
searcher (A.R.). The references of the retrieved articles and ex-
tracted reviews on the topic were scanned to identify potentially 
missed studies. At the end of this procedure, 33 independent 
studies were included in the systematic analysis and the sub-
sequent meta-analysis (Figure 1: Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses Flow chart).
The following variables were extracted from the included 
studies: authors and year of publication of the study, location 
of the study, criteria and instrument for diagnosis, criteria for 
transition to psychosis, sample size at baseline and follow-up, 
data on AP exposure (yes/no) based on the outcome (transi-
tion/no transition), duration of the follow-up, and number of 
cases that transitioned psychosis at the end of follow-up by 
group. Three aggregated subgroups were then analyzed: CHR-P 
with baseline exposure to AP, CHR-P without baseline exposure 
to AP from the same source studies, and CHR-P enrolled from 
samples that excluded individuals who were exposed to AP at 
baseline. Quality assessment was rated according to the Quality 
Assessment Tool for Observational Cohort and Cross-Sectional 
Studies. Discrepancies in extraction of data were solved by dis-
cussion within the research team.
Statistical Analysis
All analyses were carried out with the “meta” package 
(Schwarzer et al., 2015) and the “metafor” package (Viechtbauer, 
2010) running in R version 3.5.1 (R Core Team, 2018).
The outcome of the meta-analysis was the proportion of 
transition to psychosis. All proportions were estimated with 
the variance-stabilizing [Freeman and Tukey (1950)] double 
arcsine transformation, since there is evidence that it out-
performs other proposed methods (e.g., logit transformation) 
of estimating prevalence (Barendregt et  al., 2013), especially 
when the proportion of cases is expected to be small. Between-
study variance and variance of the effect size parameters 
across the population were estimated with the tau-squared 
statistics using Empirical Bayes estimator (Veroniki et  al., 
2016); its 95% CI was calculated by using the Q-Profile method 
Records identified through 
database searching
















Additional records identified 
through other sources
(n =  45)
Record titles and abstracts screened for 
eligibility (n =   1883)
Full-text articles assessed 
for eligibility (n =319)
Records excluded
(n = 1564)
Studies extracted for being 
potentially relevant to the 
topic (n = 98)
Full-text articles excluded, 
n=65
with reasons
no UHR instrument n=2
Studies included in 
qualitative synthesis
(n = 33)










/ijnp/article/24/9/710/6283708 by Biblioteche biom
ediche U
niversita' di Torino user on 29 O
ctober 2021
Copyedited by:  
Raballo et al. | 713
(Viechtbauer, 2010) with Knapp and Hartung (2003) correction. 
Continuity correction of 0.5 was applied in studies with zero 
cell frequencies.
Both fixed- and random-effects summary estimates were re-
ported along with a corresponding 95% confidence interval (CI) 
for each outcome in forest plots. Fixed-effects models estimate 
a common effect for the studies included in the meta-analysis 
(Viechtbauer, 2010). The random-effects models aim to pro-
vide inference about the average effect in the entire population 
from which the studies are expected to be drawn. Essentially, 
the random-effects model accounts for the heterogeneity of the 
studies, that is, the fact that the effects that are estimated from 
the studies come from a distribution of true effects, which de-
pend on a source of variability that is not limited to sampling 
error (Borenstein et  al., 2010). It should be borne in mind that, 
in the attempt to model some (but not all) heterogeneity in the 
studies, the random-effects model tends to inflate the role of 
small studies (Borenstein et al., 2010); in doing so, it loses power 
compared with the fixed-effects model (Jackson and Turner, 2017).
In all analyses, heterogeneity was assessed with Cochran’s 
Q and I2 statistics (Huedo-Medina et al., 2006). Cochran’s Q test 
assesses the null hypothesis that the true effect size is the same 
in all studies (Borenstein, 2020). A low P value (i.e., P < .10) of the 
Q-statistic indicates that variation in the study-specific effect 
estimates is due to heterogeneity beyond that depending on 
sampling error. The I2 statistic measures the extent to which the 
variance in observed effects reflects variance in true effects ra-
ther than sampling error (Borenstein, 2020). The higher the I2, 
the greater the impact of the variance in true effects. According 
to an agreed rule of thumb, I2 values 40% to 60% indicated mod-
erate heterogeneity, and values above 75% were considered in-
dicative of substantial heterogeneity (Higgins and Cochrane 
Collaboration, 2002).
Results
The literature search identified 33 eligible studies: 16 studies 
that allowed baseline AP exposure and specified the transition 
outcome based on AP exposure vs AP no exposure (reported in 
Table 1), and 17 studies that considered baseline AP exposure as 
exclusion criterion (reported in Table 2).
Studies that included CHR-P with AP exposure at baseline 
disproportionally used the Structured Interview for Prodromal 
Symptoms as a measure to define CHR-P status (13 out of 
16 studies: 81.2%); conversely, in the studies that included 
only CHR-P participants who were never exposed to AP, the 
Comprehensive Assessment of At Risk Mental States was the 
most used tool to define the condition (9 out of 17 studies: 52.9%).
Most studies were from European countries (19 out of 33 
studies: 57.6%), while others were from North American coun-
tries (USA and Canada: 7 out of 33 studies: 21.2%) and Asian 
countries (7 out of 33 studies: 21.2%). There were no studies from 
Central or South America or from Africa.
Those studies including CHR-P with AP exposure at base-
line were almost equally distributed from the North American 
countries (USA and Canada: 6 out of 16 studies: 37.6%), Asian 
countries (5 out of 16 studies: 31.2%), and European countries (5 
out of 16 studies: 31.2%), while the majority of studies including 
only drug-naive CHR-P patients were from European countries 
(14 out of 17 studies: 82.4%).
Compared by probability of transition to psychosis according 
to the criteria listed in each study, the 3 groups of AP-exposed, 
AP-not exposed, and AP-never exposed patients were found to 
differ both within and between studies (Figure 2, forest plot). The 
3 groups differed from each other, with the AP-exposed samples 
having higher transition rates than the AP-not exposed samples 
and the AP-never exposed samples (Table 3). The AP-not ex-
posed samples and the AP-never exposed samples did not differ 
from each other. The differences were statistically significant at 
the conservative threshold of P < .05 in both the fixed-effects and 
random-effects models (Table 3 for details).
Heterogeneity within studies was substantial, with values 
above 75% in all comparisons. However, there was no relevant 
asymmetry in the funnel plot of each group of samples, and the 
Egger test showed no relevant bias in publication (see supple-
mentary Figs. 1–3).
Discussion
The results of the present meta-analysis indicate that sample 
enrichment is not a plausible explanation for the higher risk of 
transition to psychosis of CHR-P participants who were already 
exposed to AP at the enrollment in specialized early-detection 
programs. Rather, the results further corroborate the evidence 
that baseline exposure to AP (at the moment of CHR-P assess-
ment) is a major index of enhanced, imminent risk of incurring 
a full-blown psychotic episode at follow-up (Raballo et  al., 
2020a,b).
While this is clearly an important aspect to consider for re-
fining current risk stratification (and amending some of the 
shortcomings of current CHR-P definitions; see Preti et al., 2014 
and van Os and Guloksuz, 2017), it would be essential to further 
deconstruct the nature of such phenomenon. Three main ex-
planatory hypotheses can be advanced in this respect, each of 
which warranting further, targeted empirical exploration.
Hypothesis 1
Pro-Psychotic Effect of AP in CHR-P via Sensitization or 
Neurotoxicity—AP exert per se a psychotogenic action on the brain 
of CHR-P individuals. The reason can be a sensibilization effect 
on the dopaminergic neurons because of persistent block of the 
pre- and post-synaptic receptors, causing a hypersensitivity of 
the neurons to dopaminergic discharge (Chouinard et al., 2017; 
Nakata et al., 2017; Yin et al., 2017). A second mechanism may 
be a direct toxic effect on the neurons. There is some evidence 
that long-term AP treatment may associate with brain structure 
changes (Ho et al., 2011), especially a parietal lobe reduction and 
basal ganglia increase (Huhtaniska et al., 2017). Brain structural 
changes were reported in both CHR-P individuals (Katagiri et al., 
2019) and first-episode psychosis patients (Akudjedu et al., 2020).
Hypothesis 2
Masking Effect of AP “Attenuating” the Clinical Presentation of the 
Psychotic Episode—Individuals exposed to AP may have already 
transitioned towards psychosis, yet the ongoing AP treatment at 
baseline might have prevented the psychometric identification 
of these “pharmacologically attenuated first-episode psychosis” 
cases (Raballo et al., 2020a). Strictly speaking, this group is no 
longer in a high-risk condition, but rather it has already reached 
the endpoint outcome (i.e., the first-episode psychosis) although 
unrecognized.
Hypothesis 3
Delaying Effect of AP “Postponing” Transition to Psychosis—
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enrollment in the program of care consists of individuals 
with severe ongoing symptoms and a rapidly deteriorating 
clinical picture (i.e., sufficiently alarming as to motivate the 
treating staff to initiate AP prescription before the emergence 
of full-blown positive symptoms). This subgroup might have an 
accelerated evolution towards psychosis, and the ongoing AP 
administration at enrollment temporarily delays the transition 
to psychosis so that they fulfill baseline CHR-P criteria yet 
develop a full psychotic state soon afterwards. Therefore, (1) this 
group is a hyper-CHR-P subpopulation (i.e., a subgroup with the 
highest imminent risk of transition within CHR-P), and (2) AP 
prescription is to be considered a red warning flag for enhanced 
transition to psychosis.
In favor of hypothesis 3, there are 2 randomized con-
trolled trials that tested the preventive action of low-dose 
AP against placebo in CHR-P help-seekers (McGorry et  al., 
2002; McGlashan et  al., 2006). Both studies found low-dose 
AP was able to reduce transition to psychosis in the short 
term (6  months) compared with placebo, but the protective 
effects fade at 12  months (McGlashan et  al., 2006; McGorry 
et  al., 2013). However, hypothesis 2 cannot be entirely ruled 
out by these findings. Indeed, distinguishing “pharmacologic-
ally attenuated first-episode psychosis” (hypothesis 2)  cases 
from hyper-CHR-P patients with rapid progression towards 
psychosis (hypothesis 3)  is clearly a clinical priority and an 
important step forward in the field. In this respect, time-
dependent trajectories may be a key feature to operate such 
distinction, since CHR-P patients with rapid evolution towards 
psychosis are likely to be recognized relatively early as tran-
sitioned cases, whereas “pharmacologically attenuated first-
episode psychosis” cases are presumably more likely to persist 
into an “attenuated symptom condition” until additional fac-
tors (social stress, substance use, and/or discontinuation of 
the AP treatment) intervene.
As for hypothesis 1, the best test of the hypothesis is 
knowing in detail the longitudinal clinical history of the parti-
cipants in the study. If participants were maintained under AP 
during the study, they might have benefitted from the attenu-
ation of their first-episode psychosis status until relapse into 
full-blown psychosis. Conversely, when the AP prescription has 
been suspended as per current guidelines (NICE, 2014; European 
Psychiatric Association: Schmidt et al., 2015), they might have 
been exposed to the sensibilization effect of the AP on the dopa-
minergic receptors and led by this sensibilization to an en-
hanced risk of transition to psychosis.
There was a high variability within the studies included in this 
meta-analysis. The main source of variability across the studies was 
in all likelihood the different procedures of enrollment of the parti-
cipants. Differences in the procedures of enrollment indeed led to 
samples that allowed the inclusion of participants who had already 
received or were currently prescribed AP treatment, whereas other 
samples excluded them from enrollment. Nonetheless, sample en-
richment did not seem a sufficiently powerful mechanism to ex-
plain the substantial divergence in transition prevalence between 
AP-exposed and AP-naïve CHR-P individuals. Bias in publication 
was not present in the analyzed groups. However, as can be seen 
in the provided forest plot, there were differences in transition to 
psychosis prevalence within groups not attributable to past expos-
ition to AP that might depend on the characteristics of the sample 
(age, gender proportion, comorbidity, and so on). We were not able to 
explore the role of these characteristics because they were not sys-
tematically reported in the source studies, that is, the details about 
associated characteristics by subgroup (AP exposed and not ex-
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Additional limitations should be considered. First, included 
studies are not primarily aimed to address the issue of pretest 
risk enrichment and rarely mentioned the steps of specific 
recruitment strategy. Therefore, we opted for a clinically ra-
tional epidemiologic proxy, that is, we considered studies 
with baseline AP-exposed CHR-P as putatively indicative of a 
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higher severity of the referred group (i.e., a mental state se-
vere enough to justify AP prescription instead of psychosocial 
interventions only or non-AP medications such as antidepres-
sant, anxiolytics, and mood-stabilizers). Similarly, we wished 
to analyze the impact of other non-AP drugs as well, since 
they might contribute to the baseline clinical presentation 
(e.g., non-AP medications can have an influence on reducing 
anxiety and mood oscillations as well as sleep disturbances), 
but only a few studies reported analyzable information (e.g., 
on the type and dose of medications).
Nonetheless, the results indicate that the pretest risk enrich-
ment due to the heterogeneity of sampling strategies in CHR-P 
research is unlikely to justify the apparent negative prognostic 
effect of baseline antipsychotic exposure on the risk of tran-
sition to psychosis. This further highlights the importance of 
deconstructing this phenomenon (Raballo et al., 2021), which has 
paramount implications for the treatment of psychosis and the 
prevention or mitigation of its undesired long-term outcomes.
Conclusions
This meta-analysis further investigates the prognostic impact 
of baseline AP prescription in CHR-P help-seekers and tests 
whether pre-test risk enrichment could be implicated in the 
increased meta-analytic risk of transition that characterizes 
those CHR-P with ongoing AP at inclusion. The results indi-
cate that transition prevalence in AP-naïve CHR-P is similar 
independently of whether they were enrolled in studies with 
rigorous exclusion criteria on AP exposure or more lenient 
ones (i.e., allowing the enrollment of CHR-P individuals under 
AP therapy). Therefore, pre-test risk enrichment is not impli-
cated in the observed negative prognostic effect of baseline 
antipsychotic exposure in CHR-P. The results invite a fur-
ther dissection of such phenomenon, possibly discriminating 
“pharmacologically attenuated first-episode psychosis” from 
those CHR-P in which AP prescription likely indexes a sub-
group with the highest imminent risk of transition because of 
rapidly escalating severity.
The investigation of the potential negative prognostic effect 
of AP in young help-seekers is not merely an academic topic. 
Indeed, there is increasing awareness that AP are often pre-
scribed in youth for conditions that did not receive approved 
indication, especially in youth from underserved communities 
(Olfson et al., 2015; Mackie et al., 2021). Moreover, little informa-
tion exists so far about the long-term effects of antipsychotics 
on a still-developing brain (Harrison et al., 2012), and evidence 
on safety outcomes in children and adolescents is often indirect 
or based on just 1 study (Krause et  al., 2018). Even if in some 
early-intervention services for CHR-P, AP are often used to treat 
comorbid disorders rather than emerging psychosis (Fusar-Poli 
et al., 2020; Kotlicka-Antczak et al., 2020), a proper investigation 
of their impact on the risk of transition to psychosis is man-
datory before endorsing more specific indications on their use 
(Zhang et al., 2020) or disallowing tout court their prescription 
as per recommendation 1.2.3.2 of the current NICE guidelines.
Supplementary Materials
Supplementary data are available at International Journal of 
Neuropsychopharmacology (IJNPPY) online.
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